SLC27A4: Key Regulator of Fatty Acid Transport and Inflammation

Target Name: SLC27A4

NCBI ID: G10999

SLC27A4

SLC27A4: Key Regulator of Fatty Acid Transport and Inflammation

SLC27A4 (FATP4) is a protein that is expressed in various tissues throughout the body, including the liver, heart, and kidneys. It is a key regulator of the transport of fatty acids into the mitochondria, where they can be used for energy production. SLC27A4 has also been shown to play a role in the regulation of inflammation and has been linked to a number of diseases, including obesity, type 2 diabetes, and heart disease.

SLC27A4 is a member of the SLC family of transport proteins, which are known for their ability to transport a wide variety of molecules across cell membranes. The SLC27A4 protein is composed of 27 amino acid residues and has a calculated molecular mass of 33.1 kDa. It is expressed in a variety of tissues, including the liver, heart, and kidneys, and is also found in the bloodstream.

One of the key functions of SLC27A4 is its role in the transport of fatty acids into the mitochondria. Mitochondria are organelles that are responsible for generating the energy that the body uses for most cellular processes, and they are able to do this by using fatty acids as a source of energy. SLC27A4 helps to regulate the transport of these fatty acids into the mitochondria so that they can be used for energy production.

In addition to its role in energy production, SLC27A4 has also been shown to play a key role in the regulation of inflammation. It has been shown to be involved in the production of pro-inflammatory molecules, such as reactive oxygen species (ROS) and chemokines, which can contribute to the development of inflammatory diseases. SLC27A4 has also been shown to be involved in the regulation of immune cells, which are important for fighting off infections and diseases.

SLC27A4 has also been linked to a number of diseases, including obesity, type 2 diabetes, and heart disease. Obesity, in particular, is a major risk factor for a range of diseases, including heart disease and type 2 diabetes, and SLC27A4 may be involved in the regulation of these conditions. For example, studies have shown that SLC27A4 is expressed in the fat tissue and is involved in the production of fat, which may contribute to obesity. In addition, SLC27A4 may also be involved in the regulation of insulin sensitivity, which is an important factor in the development of type 2 diabetes.

SLC27A4 has also been shown to have potential as a drug target or biomarker. For example, studies have shown that SLC27A4 can be targeted with small molecules, such as inhibitors, to reduce the production of pro-inflammatory molecules. This may have potential as a treatment for inflammatory diseases, such as heart disease and type 2 diabetes. In addition, SLC27A4 has also been shown to be involved in the regulation of cellular processes, such as cell signaling and metabolism, which may make it an attractive target for drugs that target these processes.

Overall, SLC27A4 is a protein that has important roles in a variety of cellular processes, including energy production, inflammation regulation, and cellular signaling. Its potential as a drug target or biomarker makes it an attractive target for research into a wide range of diseases. Further studies are needed to fully understand the role of SLC27A4 in these processes and to develop effective treatments for the associated conditions.

Protein Name: Solute Carrier Family 27 Member 4

Functions: Mediates the levels of long-chain fatty acids (LCFA) in the cell by facilitating their transport across cell membranes (PubMed:10518211, PubMed:12556534, PubMed:20448275, PubMed:21395585, PubMed:22022213). Appears to be the principal fatty acid transporter in small intestinal enterocytes (PubMed:20448275). Also functions as an acyl-CoA ligase catalyzing the ATP-dependent formation of fatty acyl-CoA using LCFA and very-long-chain fatty acids (VLCFA) as substrates, which prevents fatty acid efflux from cells and might drive more fatty acid uptake (PubMed:22022213, PubMed:24269233). Plays a role in the formation of the epidermal barrier. Required for fat absorption in early embryogenesis (By similarity). Probably involved in fatty acid transport across the blood barrier (PubMed:21395585). Indirectly inhibits RPE65 via substrate competition and via production of VLCFA derivatives like lignoceroyl-CoA. Prevents light-induced degeneration of rods and cones (By similarity)

The "SLC27A4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC27A4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets